3 / 20
Page 20
Notes:
allied
academies
J Med Oncl Ther 2017 | Volume 2 Issue 4
Oncology and Biomarkers Summit
November 27-28, 2017 | Atlanta, USA
Annual Congress on
Inhibition of breast cancer bonemetastasis and pancreatic and colon cancer by synthetic curcumin analogs
Mamoru Shoji
Emory University, USA
C
urcumin (diferuloylmethane) is a β-diketone constituent of
the turmeric. It is used as a spice to give a specific flavor and
yellow color to curry. However, its clinical efficacy is poor because
of its low solubility. He worked with professors Liotta and Snyder
at the Chemistry department to synthesize a series of novel
monocarbonyl analogs of curcumin (MACs) approximately 100
analogs including EF24, EF31 and UBS109. Dr. Shoji’s laboratory
and the NCI tested the analogs for the anticancer activity. The NCI
determined the mean growth inhibitory concentration (GI-50) of
EF24, curcuminandcisplatinon theNCI-60cancer cell panel,which
are 0.7 μM, 7.3 μM and 9.5 μM, respectively. MACs do not kill
normal breast cells MCF-10A but kill all cancer cells tested (KB-3-1,
TU212, MiaPaCa, SE-Mel-28, RPMI-7951, andMDA-MB- 231 cells)
at concentrations (0-20μM).MACs inhibitNF-κBby inhibiting IKK-α
andIKK-β.UBS109inhibitedbreastcancermetastasisandosteolysis
by inhibiting osteoclasts precursors and osteoclasts, but promotes
new bone formation by stimulating osteoblast activation. UBS109
and EF24 inhibited four pancreatic cancer cell lines 100% at less
than 1.25 μM, whereas gemcitabine did not up to 20 μM. UBS109
significantly inhibitedMiaPaCa-2 pancreatic cancer xenografts and
colon cancer (HT-29 and HCT-116) xenografts inmice at 25mg/kg,
iv once a week better than a combination of oxaliplatin (5 mg/kg)
and 5FU (30mg/kg) iv.
Speaker Biography
Mamoru Shoji has developed synthetic monocarbonyl analogs of curcumin (MACs) out of the
100syntheticanalogswithDrs.DCLiotta,JPSnyder,BKAdamsandothercolleagues.Heandhis
colleagues try tomove the analogs for clinical trials.
e:
mshoji@emory.edu